Business Context and Reporting Period
This Form 8-K reports on events occurring on October 20, 2015, for Cerecor Inc. (Note: The request metadata lists "Avalo Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Cerecor Inc.). The primary event is the closing of the Company's Initial Public Offering (IPO).
Key Financial Metrics and Transaction Details
- IPO Structure: Sold 4,000,000 units at a public offering price of $6.50 per unit.
- Unit Composition: Each unit consists of one share of Common Stock, one Class A warrant (to purchase one share), and one Class B warrant (to purchase one-half share).
- Underwriter Options (UPOs): Sold unit purchase options to underwriters for $100 aggregate to purchase up to 40,000 units (1% of IPO volume).
- UPO Exercise Price: $7.48 per unit (115% of the IPO price).
- Warrant Exercise Prices (via UPOs): Class A warrants at $5.23; Class B warrants at $4.49.
- Capitalization: The Amended and Restated Certificate of Incorporation authorizes 200,000,000 shares of common stock and 5,000,000 shares of undesignated preferred stock.
Note: This filing does not provide specific revenue, profit, cash flow, or debt figures as it is a transactional report regarding the IPO closing and corporate governance changes.
Material Changes
- Public Listing: Transition from a private entity to a public company via the IPO closing.
- Corporate Governance: Adoption of an Amended and Restated Certificate of Incorporation and Bylaws effective October 20, 2015.
- Stockholder Rights: Prohibition of stockholder action by written consent; special meetings may only be called by the Chairman, CEO, or Board.
- Board Structure: Implementation of a staggered board with three classes of directors serving three-year terms.
- Preferred Stock: Elimination of previously existing preferred stock series; authorization of new undesignated preferred stock.
Outlook, Risks, and Contingencies
- Registration Rights: The UPOs include one demand registration right at the Company's expense, one at the holder's expense, and unlimited "piggyback" rights for five years.
- Warrant Expirations: Class B warrants expire April 20, 2017; Class A warrants expire October 20, 2018. UPOs expire October 14, 2020.
- Exercise Adjustments: Following the expiration of specific warrant classes, the UPO exercise price and deliverables adjust (e.g., exercisable only for Common Stock after Class A warrant expiration).
Investor Verification Checklist
- Verify the total gross proceeds from the IPO (4,000,000 units x $6.50) and net proceeds after underwriting discounts.
- Confirm the dilution impact of the 40,000 unit purchase options (UPOs) held by underwriters.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for specific anti-takeover provisions.
- Check the Company's cash position post-IPO to assess runway for clinical development (not detailed in this 8-K).
- Monitor the exercise dates and pricing adjustments for the UPOs and associated warrants.